FDA Approves First CAR T-Cell Therapy for Marginal Zone Lymphoma In the US - fda.gov
The U.S. Food and Drug Administration today approved a new indication for Breyanzi (Lisocabtagene maraleucel) as the first Chimeric Antigen Receptor (CAR) T-cell therapy in the U.S.
Comments